CD274 and esophageal squamous cell carcinoma: Of the 67 patients assigned to the placebo–chemotherapy group, 59 (88.1%) had ESCC, 36 (53.7%) had PD-L1 CPS ≥ 10, and 32 (47.8%) had ESCC PD-L1 CPS ≥ 10.